One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Record caution: Read the product renal-toxicity warning as well as the KDIGO dose guidance. These are different clinical decisions, not a single automated recommendation.
The official label gives a qualitative reduction warning. KDIGO 2024 supplies a disease-specific indexed-eGFR reduction instruction; these differ in specificity rather than representing a universally applicable replacement label.
What to reconcile: Match lupus-nephritis context, starting exposure and retinal monitoring. Worsening renal function can also represent labeled drug toxicity, not only the underlying disease. Do not transfer the nephritis recommendation to malaria without review.
Open this note and its source referencesThe label states that dose reduction may be necessary in renal or hepatic disease but supplies no percentage or eGFR dose table. Renal impairment is also a retinal-toxicity risk factor; apply the higher-risk ophthalmic monitoring instructions.
Proteinuria, with or without a moderate GFR reduction, has been reported. Consider drug-induced phospholipidosis as a possible cause of kidney injury in patients with underlying connective-tissue disease. Discontinue PLAQUENIL if renal toxicity is suspected or demonstrated on biopsy. A worsening creatinine value is therefore not automatically attributed to lupus activity or managed solely by a routine dose reduction.
RDM38-official-hydroxychloroquine-plaquenil-4ae873802e-C1 · Source locator: Sections 8.6, 5.2 and 5.11
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=hydroxychloroquine-plaquenil&s1=RDM38-official-hydroxychloroquine-plaquenil-4ae873802e&h1=8ce7be38242341e9c8cfea61261b3333708b0ac2c98a056258bc1c68558bd3a7